
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2545624/publications.pdf Version: 2024-02-01



TEDDALLASHO

#	Article	IF	CITATIONS
1	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	0.6	575
2	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
3	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	2.5	243
4	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
5	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	2.0	176
6	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood, 2012, 120, 4168-4171.	0.6	146
7	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 2014, 124, 2465-2466.	0.6	135
8	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	1.2	134
9	Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 2015, 21, 1473-1480.	15.2	128
10	Validation of the revised international prognostic score of thrombosis for essential thrombocythemia ( <scp>IPSET</scp> â€thrombosis) in 585 Mayo clinic patients. American Journal of Hematology, 2016, 91, 390-394.	2.0	106
11	Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. British Journal of Haematology, 2006, 135, 683-687.	1.2	103
12	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
13	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 2018, 32, 1189-1199.	3.3	102
14	Driver mutations and prognosis in primary myelofibrosis: Mayo areggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	2.0	94
15	<i>ASXL1</i> mutations are frequent and prognostically detrimental in <i>CSF3R</i> â€mutated chronic neutrophilic leukemia. American Journal of Hematology, 2015, 90, 653-656.	2.0	76
16	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia, 2018, 32, 2274-2278.	3.3	75
17	Targeted nextâ€generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSSâ€R. American Journal of Hematology, 2017, 92, 1311-1317.	2.0	73
18	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARSâ€T) and the role of nextâ€generation sequencing. American Journal of Hematology, 2016, 91, 492-498.	2.0	70

#	Article	IF	CITATIONS
19	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	2.5	68
20	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	3.3	68
21	Targeted next generation sequencing and identification of risk factors in <scp>W</scp> orld <scp>H</scp> ealth <scp>O</scp> rganization defined atypical chronic myeloid leukemia. American Journal of Hematology, 2017, 92, 542-548.	2.0	64
22	Nextâ€generation sequencing in systemic mastocytosis: Derivation of a mutationâ€augmented clinical prognostic model for survival. American Journal of Hematology, 2016, 91, 888-893.	2.0	60
23	DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61.	2.0	60
24	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. American Journal of Hematology, 2018, 93, 1474-1484.	2.0	56
25	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
26	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	2.0	51
27	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	2.0	50
28	Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer Journal, 2018, 8, 29.	2.8	49
29	Therapy relatedâ€chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from <i>de novo</i> CMML. American Journal of Hematology, 2018, 93, 65-73.	2.0	49
30	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 2016, 91, 503-506.	2.0	47
31	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1488-1493.	0.6	47
32	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	5.8	44
33	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia, 2018, 32, 1254-1258.	3.3	42
34	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer Journal, 2018, 8, 12.	2.8	41
35	Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645.	2.0	40
36	Nucleophosmin 1 ( <i>NPM1</i> ) mutations in chronic myelomonocytic leukemia and their prognostic relevance. American Journal of Hematology, 2017, 92, E614-E618.	2.0	34

#	Article	IF	CITATIONS
37	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838.	1.2	32
38	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 2020, 34, 656-661.	3.3	32
39	Prefibrotic <i>versus</i> overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. British Journal of Haematology, 2018, 182, 594-597.	1.2	31
40	<i>CALR</i> mutation studies in chronic neutrophilic leukemia. American Journal of Hematology, 2014, 89, 450-450.	2.0	29
41	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematology American Society of Hematology Education Program, 2020, 2020, 450-459.	0.9	29
42	<i>JAK2</i> exon 12 mutated polycythemia vera: Mayo areggi MPN Alliance study of 33 consecutive cases and comparison with <i>JAK2</i> V617F mutated disease. American Journal of Hematology, 2018, 93, E93-E96.	2.0	27
43	CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer Journal, 2018, 8, 21.	2.8	26
44	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	2.8	26
45	<i>ASXL1</i> and <i>CBL</i> mutations are independently predictive of inferior survival in advanced systemic mastocytosis. British Journal of Haematology, 2016, 175, 534-536.	1.2	25
46	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia, 2018, 32, 1850-1856.	3.3	25
47	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	2.0	25
48	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 2020, 34, 2519-2524.	3.3	25
49	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer Journal, 2018, 8, 82.	2.8	24
50	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategoryâ€specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466.	2.0	24
51	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood, 2022, 139, 1066-1079.	0.6	24
52	Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology American Society of Hematology Education Program, 2020, 2020, 460-464.	0.9	22
53	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the <i>FIP1L1â€PDGFRA</i> mutation. American Journal of Hematology, 2016, 91, E10-1.	2.0	20
54	Targeted next generation sequencing of <scp>PDGFRB</scp> rearranged myeloid neoplasms with monocytosis. American Journal of Hematology, 2016, 91, E12-4.	2.0	20

#	Article	IF	CITATIONS
55	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	1.4	20
56	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2018, 8, 18.	2.8	19
57	Screening for <i><scp>ASXL</scp>1</i> and <i><scp>SRSF</scp>2</i> mutations is imperative for treatment decisionâ€making in otherwise low or intermediateâ€1 risk patients with myelofibrosis. British Journal of Haematology, 2018, 183, 678-681.	1.2	19
58	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	2.0	19
59	Mayo <i>CALR</i> mutation type classification guide using alpha helix propensity. American Journal of Hematology, 2018, 93, E128-E129.	2.0	18
60	MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer Journal, 2018, 8, 121.	2.8	17
61	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nature Communications, 2022, 13, 1434.	5.8	17
62	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658.	2.8	16
63	<i>U2AF1</i> mutation variants in myelodysplastic syndromes and their clinical correlates. American Journal of Hematology, 2018, 93, E146-E148.	2.0	15
64	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. Blood, 2011, 118, 3803-3803.	0.6	15
65	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood, 2015, 126, 354-354.	0.6	14
66	Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Annals of Hematology, 2016, 95, 1185-1189.	0.8	13
67	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leukemia and Lymphoma, 2018, 59, 2998-3001.	0.6	13
68	Juvenile myelomonocytic leukemia – A bona fide RASopathy syndrome. Best Practice and Research in Clinical Haematology, 2020, 33, 101171.	0.7	13
69	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. Blood, 2020, 136, 27-28.	0.6	13
70	Concurrent activating <i><scp>KIT</scp></i> mutations in systemic mastocytosis. British Journal of Haematology, 2016, 173, 153-156.	1.2	12
71	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 32.	2.8	12
72	World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer Journal. 2019. 9. 29.	2.8	12

5

#	Article	IF	CITATIONS
73	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	2.0	12
74	The germline <i>JAK2</i> GGCC (46/1) haplotype and survival among 414 molecularlyâ€annotated patients with primary myelofibrosis. American Journal of Hematology, 2019, 94, 299-305.	2.0	11
75	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662.	0.6	11
76	ldentification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mateâ€pair sequencing. American Journal of Hematology, 2013, 88, 741-746.	2.0	10
77	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirtyâ€nine patients. American Journal of Hematology, 2018, 93, 1347-1357.	2.0	10
78	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very longâ€lived patients. American Journal of Hematology, 2019, 94, 286-290.	2.0	10
79	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp> â€2 pandemic. American Journal of Hematology, 2020, 95, E203-E208.	2.0	10
80	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. Blood, 2013, 122, 1510-1510.	0.6	10
81	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	2.0	9
82	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	2.8	9
83	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
84	Sustained, complete response to pexidartinib in a patient with <scp><i>CSF1R</i></scp> â€nutated Erdheim–Chester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
85	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. American Journal of Hematology, 2018, 93, E235-E238.	2.0	8
86	Response to erythropoiesisâ€stimulating agents in patients with WHOâ€defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). British Journal of Haematology, 2020, 189, e104-e108.	1.2	8
87	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 2021, 35, 644-649.	3.3	8
88	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. Blood Cancer Journal, 2018, 8, 118.	2.8	7
89	Atypical CML- the role of morphology and precision genomics. Best Practice and Research in Clinical Haematology, 2020, 33, 101133.	0.7	7
90	Concomitant Analysis of EZH2 and ASXL1 Mutations In Myelofibrosis, Chronic Myelomonocytic Leukemia and Blast-Phase Myeloproliferative Neoplasms. Blood, 2010, 116, 3070-3070.	0.6	7

#	Article	IF	CITATIONS
91	AKT activation is a feature of CALR mutant myeloproliferative neoplasms. Leukemia, 2019, 33, 271-274.	3.3	6
92	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia, 2021, 35, 3329-3333.	3.3	6
93	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330.	2.0	6
94	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. Blood, 2016, 128, 948-948.	0.6	6
95	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence Blood, 2006, 108, 116-116.	0.6	6
96	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	2.8	5
97	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	0.6	5
98	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations Blood, 2006, 108, 2680-2680.	0.6	5
99	Aurora A Kinase Is a Novel Therapeutic Target In The Myeloproliferative Neoplasms. Blood, 2013, 122, 109-109.	0.6	5
100	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	0.6	5
101	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. Blood, 2011, 118, 1751-1751.	0.6	5
102	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	2.8	5
103	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leukemia Research, 2022, 116, 106818.	0.4	5
104	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. Leukemia, 2019, 33, 780-785.	3.3	4
105	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105.	0.6	4
106	Comprehensive Cytokine Profiling in Systemic Mastocytosis: Prognostic Relevance of Increased Plasma IL-2R Levels Blood, 2012, 120, 2836-2836.	0.6	4
107	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. Blood, 2016, 128, 1123-1123.	0.6	4
108	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 110-110.	0.6	4

#	Article	IF	CITATIONS
109	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. Blood, 2018, 132, 1761-1761.	0.6	4
110	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	0.6	4
111	Phenotypic correlates and prognostic outcomes of <scp><i>TET2</i></scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	2.0	3
112	Remarkable stability in clonal hematopoiesis involving leukemiaâ€driver genes in patients without underlying myeloid neoplasms. American Journal of Hematology, 2021, 96, E392-E396.	2.0	3
113	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	0.6	3
114	Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms. Blood, 2020, 136, 1-1.	0.6	3
115	Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Blood, 2010, 116, 3068-3068.	0.6	3
116	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. Blood, 2010, 116, 4112-4112.	0.6	3
117	Aberrant Megakaryocyte Gene Expression Contributes to Primary Myelofibrosis Blood, 2012, 120, 2867-2867.	0.6	3
118	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
119	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. Blood, 2015, 126, 55-55.	0.6	3
120	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. Blood, 2016, 128, 4249-4249.	0.6	3
121	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	0.6	3
122	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. Blood, 2016, 128, 1987-1987.	0.6	3
123	<i>SF3B1</i> -mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	1.7	3
124	Practiceâ€relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. American Journal of Hematology, 2018, 93, E383-E386.	2.0	2
125	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of <i>TET2</i> and <i>ZRSR2</i> mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving <i>CDK2NA/2NB</i> and <i>MTAP</i> . American Journal of Hematology, 2020, 95, E31-E34.	2.0	2
126	Novel therapeutic targets for chronic myelomonocytic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101244.	0.7	2

#	Article	IF	CITATIONS
127	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	0.6	2
128	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. Blood, 2015, 126, 828-828.	0.6	2
129	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. Blood, 2016, 128, 4247-4247.	0.6	2
130	Low JAK2V617F Allele Burden in Primary Myelofibrosis, Compared to Either a Higher Allele Burden or Unmutated Status, Predicts Inferior Overall and Leukemia-Free Survival Blood, 2007, 110, 676-676.	0.6	2
131	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	0.6	2
132	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E164-E167.	2.0	1
133	Genetic predictors of response to specific drugs in primary myelofibrosis. Blood Cancer Journal, 2018, 8, 120.	2.8	1
134	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. Blood, 2018, 132, 4301-4301.	0.6	1
135	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	0.6	1
136	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	0.6	1
137	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. Blood, 2019, 134, 3003-3003.	0.6	1
138	Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,. Blood, 2011, 118, 3850-3850.	0.6	1
139	Chronic Neutrophilic Leukemia With Concurrent CSF3R and SETBP1 Mutations: Single Colony Clonality Studies, In Vitro Sensitivity To JAK Inhibitors and Lack Of Treatment Response To Ruxolitinib. Blood, 2013, 122, 2830-2830.	0.6	1
140	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. Blood, 2015, 126, 1599-1599.	0.6	1
141	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	0.6	1
142	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. Blood, 2015, 126, 350-350.	0.6	1
143	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. Blood, 2016, 128, 4248-4248.	0.6	1
144	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. Blood, 2016, 128, 4343-4343.	0.6	1

#	Article	IF	CITATIONS
145	Genomic Changes Associated with Leukemic Transformation of Myeloproliferative Disorders Blood, 2008, 112, 3371-3371.	0.6	1
146	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma Blood, 2009, 114, 925-925.	0.6	1
147	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 1756-1756.	0.6	1
148	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. Blood, 2016, 128, 3111-3111.	0.6	1
149	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). Blood, 2019, 134, 4182-4182.	0.6	1
150	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. Blood, 2021, 138, 2164-2164.	0.6	1
151	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia, 2022, 36, 1693-1696.	3.3	1
152	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.4	0
153	Cytogenetic Profile, JAK2V617F Mutational Status, and Response to Drug Therapy in Myelofibrosis with Myeloid Metaplasia Blood, 2005, 106, 2591-2591.	0.6	Ο
154	Single Nucleotide Polymorphism (SNP) Analysis of JAK2 and Relevant Cytokine Receptor Genes in Myeloproliferative Disorders Blood, 2006, 108, 661-661.	0.6	0
155	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level ≥ 10 g/dL Blood, 2007, 110, 3555-3555.	0.6	Ο
156	Pruritus in Polycythemia Vera Is More Prevalent in Non-Smokers and Is Independently Associated with a Lower Risk of Arterial Thrombosis Blood, 2007, 110, 2550-2550.	0.6	0
157	JAK2V617F Mutation Screening as Part of the Hypercoagulable Workup in the Absence of Splanchnic Vein Thrombosis: Assessment of Value in a Series of 664 Consecutive Patients Blood, 2007, 110, 3191-3191.	0.6	Ο
158	Revisiting Mastocytosis in Adults: A Mayo Clinic Case Series of 342 Patients Including Information on KITD816V and JAK2V617F Blood, 2008, 112, 1757-1757.	0.6	0
159	IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2010, 116, 4009-4009.	0.6	Ο
160	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. Blood, 2011, 118, 3795-3795.	0.6	0
161	Prognostic Irrelevance of Vitamin D Insufficiency in Myeloproliferative Neoplasms and De Novo Myelodysplastic Syndromes. Blood, 2011, 118, 5158-5158.	0.6	Ο
162	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971.	0.6	0

#	Article	IF	CITATIONS
163	Pruritus in Primary Myelofibrosis: Clinical and Laboratory Correlates. Blood, 2011, 118, 5154-5154.	0.6	О
164	CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts. Blood, 2011, 118, 2807-2807.	0.6	0
165	Gene Expression Profiling within the Context of JAK Inhibitor Therapy for Myelofibrosis: Correlation with Treatment Effect and Anemia Response. Blood, 2012, 120, 1751-1751.	0.6	Ο
166	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711.	0.6	0
167	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with ≥ 1% Ring Sideroblasts Blood, 2012, 120, 2803-2803.	0.6	О
168	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. Blood, 2012, 120, 430-430.	0.6	0
169	Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis Blood, 2012, 120, 2831-2831.	0.6	0
170	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. Blood, 2013, 122, 4060-4060.	0.6	0
171	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048.	0.6	0
172	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). Blood, 2015, 126, 4067-4067.	0.6	0
173	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. Blood, 2015, 126, 4062-4062.	0.6	0
174	Molecular Correlates of Anemia in Primary Myelofibrosis. Blood, 2015, 126, 4068-4068.	0.6	0
175	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 2864-2864.	0.6	Ο
176	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259.	0.6	0
177	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986.	0.6	Ο
178	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1988-1988.	0.6	0
179	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1989-1989.	0.6	0
180	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. Blood, 2018, 132, 4300-4300.	0.6	0

#	Article	IF	CITATIONS
181	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. Blood, 2018, 132, 3034-3034.	0.6	0
182	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. Blood, 2018, 132, 582-582.	0.6	0
183	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. Blood, 2018, 132, 1767-1767.	0.6	0
184	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	0.6	0
185	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. Blood, 2018, 132, 3050-3050.	0.6	о
186	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. Blood, 2018, 132, 3033-3033.	0.6	0
187	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. Blood, 2018, 132, 4291-4291.	0.6	0
188	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. Blood, 2018, 132, 3036-3036.	0.6	0
189	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. Blood, 2018, 132, 3100-3100.	0.6	0
190	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. Blood, 2018, 132, 3044-3044.	0.6	0
191	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. Blood, 2018, 132, 1771-1771.	0.6	0
192	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 4232-4232.	0.6	0
193	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. Blood, 2019, 134, 3005-3005.	0.6	Ο
194	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2981-2981.	0.6	0
195	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	0.6	Ο
196	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2592-2592.	0.6	0
197	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 3684-3684.	0.6	0
198	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 1470-1470.	0.6	0

#	Article	IF	CITATIONS
199	Tumor Mutational Burden in Histiocytic Neoplasms. Blood, 2021, 138, 3634-3634.	0.6	0
200	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2020, 136, 31-32.	0.6	0
201	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. Blood, 2020, 136, 10-11.	0.6	0
202	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
203	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0